Compare GHI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
| Metric | GHI | MDXH |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 167.8M |
| IPO Year | N/A | 2021 |
| Metric | GHI | MDXH |
|---|---|---|
| Price | $7.13 | $3.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $13.00 | $7.67 |
| AVG Volume (30 Days) | ★ 202.0K | 118.6K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | ★ 21.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $26,247,399.00 | ★ $103,069,000.00 |
| Revenue This Year | $201.02 | $23.34 |
| Revenue Next Year | $2.87 | $22.98 |
| P/E Ratio | $40.84 | ★ N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $6.01 | $1.35 |
| 52 Week High | $13.29 | $5.33 |
| Indicator | GHI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 47.72 |
| Support Level | $6.52 | $3.20 |
| Resistance Level | $7.35 | $3.58 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 69.74 | 70.00 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.